cilostazol has been researched along with pioglitazone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kastrati, A; Schömig, A; Wessely, R | 1 |
| Douglas, JS | 1 |
| Shinohara, Y | 1 |
| Abdallah, DM; El-Abhar, HS; Ragab, D | 1 |
3 review(s) available for cilostazol and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator | 2010 |
4 other study(ies) available for cilostazol and pioglitazone
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prevention of restenosis by systemic drug therapy: back to the future?
Topics: Cilostazol; Controlled Clinical Trials as Topic; Coronary Restenosis; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents; Humans; Phosphodiesterase Inhibitors; Pioglitazone; Placebos; Stents; Tetrazoles; Thiazolidinediones; Tunica Intima | 2005 |
Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Blood Urea Nitrogen; Caspase 1; Cell Adhesion Molecules; Cilostazol; Creatinine; Cystatin C; Dose-Response Relationship, Drug; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Interleukin-18; Kidney; Lipocalin-2; Lipocalins; Male; Nitric Oxide Synthase Type II; Peroxidase; Phosphodiesterase 3 Inhibitors; Pioglitazone; PPAR gamma; Protective Agents; Proto-Oncogene Proteins; Random Allocation; Rats, Wistar; Reperfusion Injury; Tetrazoles; Thiazolidinediones; Vascular Cell Adhesion Molecule-1 | 2014 |